US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery Market Research Reports & Industry Analysis

RSS Feeds

Drug Discovery Industry Research & Market Reports

6  7  8  9    11    13  14  15  
Astringent In The Compositions For The Treatement Of Cold Sore : Patent Overview
7/8/2016 | published by: Mordor Intelligence LLP
... are usually classified into three groups according to their mode of action: (1) those that decrease the blood supply by narrowing the small blood vessels (e.g., epinephrine and cocaine), (2) those that abstract water from ...  |  read more...
USD 500
Tankyrase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 5 or Poly [ADP Ribose] Polymerase 5A or TRF1 Interacting Ankyrin Related ADP Ribose Polymerase or TNKS or EC 2.4.2.30) - Pipeline Review, H2 2016
8/10/2016 | published by: Global Markets Direct
... Markets Direct’s, ‘Tankyrase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 5 or Poly [ADP Ribose] Polymerase 5A or TRF1 Interacting Ankyrin Related ADP Ribose Polymerase or TNKS or EC 2.4.2.30) - Pipeline Review, H2 2016’, provides ...  |  read more...
USD 3,500
Astringent In The Compositions For The Treatement Of Candidiasis : Patent Overview
7/8/2016 | published by: Mordor Intelligence LLP
... usually classified into three groups according to their mode of action: (1) those that decrease the blood supply by narrowing the small blood vessels (e.g., epinephrine and cocaine), (2) those that abstract water from the ...  |  read more...
USD 500
Biotechnology (Pharmaceuticals) (GLOBAL) - Industry Report
8/1/2016 | published by: Plimsoll Publishing Ltd.
... MEDIVIR AB. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Biotechnology (Pharmaceuticals) (GLOBAL) analysis is ideal for anyone wanting to: See the market leaders ...  |  read more...
USD 1,480
Breast Cancer Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... metastatic setting, the overall survival remains below five years. There are today 636 companies plus partners developing 706 drugs targeting breast cancer in development. In addition, there are 7 suspended drugs and the accumulated number ...  |  read more...
USD 6,750
Angiogenesis in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... of ceased drugs over the last years amount to another 218 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are ...  |  read more...
USD 6,750
Protein Kinase Inhibitors in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there ...  |  read more...
USD 6,750
Immunotherapy in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 830 companies plus partners developing 1578 cancer immunotherapy drugs in 4062 developmental projects in cancer. In addition, there are 19 suspended ...  |  read more...
USD 11,025
Hematological Cancers Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... hematological cancer drugs in 2542 developmental projects in cancer. In addition, there are 12 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 308 drugs. Hematological Cancers Drug ...  |  read more...
USD 8,850
Melanoma Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... five-year survival of advanced patients remains below 20%. There are today 374 companies plus partners developing 403 drugs targeting melanoma in development. In addition, there are 2 suspended drugs and the accumulated number of ceased ...  |  read more...
USD 6,750
Liver Cancer Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... over the last years amount to another 65 drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 221 different ...  |  read more...
USD 4,485
Brain Cancer Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are today ...  |  read more...
USD 6,750
Peptides in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... of ceased drugs over the last years amount to another 148 drugs. Peptides In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are ...  |  read more...
USD 6,750
Radiation Therapy in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 150 drugs. Radiation Therapy In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,750
Gene Therapy in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 105 drugs. Gene Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 6,750
Cytokine Therapy in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... number of ceased drugs over the last years amount to another 11 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified ...  |  read more...
USD 4,485
Cellular Therapy in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 66 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 4,485
Biologicals in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... 2823 biological drugs in 6088 developmental projects in cancer. In addition, there are 25 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 1050 drugs. Biologicals In Oncology ...  |  read more...
USD 11,025
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... 163 companies plus partners developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount ...  |  read more...
USD 6,750
Wnt Signaling Pathway in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... today 228 companies plus partners developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years ...  |  read more...
USD 6,750
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... several human malignancies include leukemias, gastrointestinal stromal tumors and mastocytomas. There are today 248 companies plus partners developing 346 Kit receptor pathway targeting drugs in 1506 developmental projects in cancer. In addition, there are 3 ...  |  read more...
USD 6,750
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 309 companies plus partners ...  |  read more...
USD 6,750
IL-1 Signaling Pathway in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 111 companies plus partners developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer. In addition, ...  |  read more...
USD 4,485
IL-3 Signaling Pathway in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... in 1225 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 131 drugs. Il-3 Signaling Pathway In Oncology Drug ...  |  read more...
USD 6,750
IL-4 Signaling Pathway in Oncology Drug Pipeline Update
8/4/2016 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 105 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
USD 6,750
6  7  8  9    11    13  14  15